This is a routine tax-withholding sale tied to equity vesting, not a discretionary insider disposition. No further insider sales are signaled. Monitor for any larger insider filings (Form 4) that might indicate a change in sentiment.
FATE drugs
FATE drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 3 $2.04entry
- T+1 · 13d ago +2.45%α +0.80% · $2.09
- T+5 · 7d ago −13.24%α −12.65% · $1.77
- T+9 · todayOpen
- T+20 · in 15d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Kamal Adawi, an officer of Fate Therapeutics, filed a Form 144 notice of intent to sell 6,582 shares of common stock, valued at approximately $13,525. The sale is to cover a tax obligation from the settlement of a vested equity award. The filing is a routine, small insider sale related to tax withholding and carries no material directional signal.
Key Facts
- Insider Kamal Adawi (Officer) filed Form 144 to sell 6,582 shares of Fate Therapeutics common stock.
- The approximate market value of the proposed sale is $13,524.69.
- The sale is to cover a tax obligation from the settlement of a vested equity award.
- The proposed sale date is November 3, 2026.
- The shares were acquired on November 2, 2026 via restricted stock vesting from the issuer.
Financial Impact
Proceeds of approximately $13,525, representing a de minimis fraction of the officer's likely holdings and less than 0.01% of the company's $260M market cap.
Risk Factors
- None material from this filing alone.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001959173-26-007696 |
| Document: 0001959173-26-007696-index.html | 0001959173-26-007696 |
| Document: 0001959173-26-007696.txt | 0001959173-26-007696 |
Track record
21 reports on FATE
4 of 8 bullish or bearish reports moved the stock their way by T+5. Best: +30.25% at T+5 after the Nov 5, 2026 report. 9 of 10 went positive at some point.
Filters
- Nov 13, 20264d ago EFFECT Bearish 5/10 Entry $1.28 Now $1.14 +10.94% settles Nov 20
- Nov 12, 20264d ago 424B5 Bearish 4/10 Entry $1.28 Now $1.14 +10.94% settles Nov 20
- Nov 9, 20267d ago SC 13D/A Neutral 2/10 Entry $1.77 Now $1.14 −35.59% settles Nov 17
- Nov 5, 202611d ago S-3 Neutral 3/10 Entry $1.84 to $1.28 Now $1.14 −37.87% ▼ −30.25% −32.84% vs SPY
- Nov 5, 202611d ago 424B5 Bearish 5/10 Entry $1.84 to $1.28 Now $1.14 +37.87% ▲ +30.25% +32.84% vs SPY
- Nov 5, 202611d ago 8-K Bearish 5/10 Entry $1.84 to $1.28 Now $1.14 +37.87% ▲ +30.25% +32.84% vs SPY
- Nov 5, 202611d ago 8-K Neutral 4/10 No price data
- Nov 5, 202611d ago Press Release Neutral 4/10 Entry $1.85 to $1.34 Now $1.14 −38.38% ▼ −27.57% −30.86% vs SPY
- Nov 4, 202612d ago Institutional Cluster Neutral 3/10 Entry $2.09 to $1.61 Now $1.14 −45.45% ▼ −23.21% −22.29% vs SPY
- Nov 3, 202613d ago 144 Neutral 2/10 Viewing Entry $2.04 to $1.77 Now $1.14 −44.12% ▼ −13.24% −12.65% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers